ClinicalTrials.gg
CompletedNCT06472284Updated May 13, 2026Results posted

TetraGraph in Rocuronium Infusions

An interventional study of TetraGraph in Surgery, sponsored by Joseph D. Tobias. Completed at 1 site in United States. Open to participants aged 28 Days to 18 Years. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Joseph D. Tobias · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
28 Days to 18 Years
Sex
All
01

Study summary

This is a prospective, non-blinded study to evaluate rocuronium infusion requirements using the TetraGraph Neuromuscular Transmission Monitor during surgical procedures in patients less than 18 yrs. of age.

02

Conditions studied

  • Surgery
03

In context

Lead sponsor

Joseph D. Tobias is the lead sponsor of 28 studies on the registry; 4 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
28 Days to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients less than 18 years of age
  • classification (ASA) 1-4
  • Patients undergoing a surgical procedure with general anesthesia and requiring the continuous administration of rocuroniuim

Exclusion criteria

Exclusion Criteria:

  • Patients less than 28 days old
  • Patients with history of a progressive or degenerative peripheral neurologic or neuropathic disorder
  • Patients undergoing a surgical procedure in which neuromuscular blockade is not required
  • Edematous patients
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Rocuronium infusion

    Patients who are scheduled for elective, urgent or emergent surgery requiring the continuous infusion of the neuromuscular blocking agent, rocuronium.

    Device: TetraGraph

Interventions

  • DeviceTetraGraph

    etraGraph is a unique, EMG-based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.

06

What researchers measure

Primary outcomes

  1. Rocuronium Bolus Dose

    Amount of rocuronium administered in a bolus dose during induction of anesthesia.

    Time frame: During the surgery (2-8 hrs.)

  2. Rocuronium Infusion Dose

    The amount of rocuronium given by continuous infusion in mg/kg/hr to maintain one twitch of the train of four (TOF)

    Time frame: During surgery (2-8 hrs.)

  3. Maximum Dose of Rocuronium

    The maximum dose of rocuronium administered by a continuous infusion per patient to maintain one twitch of the train of four (TOF)

    Time frame: During the surgery (2-8 hrs.)

Secondary outcomes

  1. Rocuronium Infusion Time

    Amount of time in minutes that patients received rocuronium infusion.

    Time frame: During the surgery (2-8 hrs.)

  2. Rocuronium Rescue Boluses

    The number of patient that received rescue boluses of rocuronium in addition to the infusion to maintain one twitch of the train of four (TOF)

    Time frame: During the surgery (2-8 hrs.)

  3. Anesthesia Time

    The total amount of time patients were under anesthesia care in minutes.

    Time frame: During the surgery (2-8 hrs.)

  4. Surgical Time

    The total amount of time from first incision to closure in minutes.

    Time frame: During the surgery (2-8 hrs.)

07

Results

Posted May 13, 2026

Participant flow

Participant flow — Overall Study
MilestoneRocuronium Infusion
Started50
Completed48
Not completed2
Withdrew: Surgical procedure canceled1
Withdrew: Physician decision1

Outcome measures

PrimaryRocuronium Bolus Dose

Amount of rocuronium administered in a bolus dose during induction of anesthesia.

Time frame:
During the surgery (2-8 hrs.)
Reported as:
Median · mg/kg
Rocuronium Bolus Dose
mg/kgRocuronium Infusion
Rocuronium Bolus Dose0.8 (0.7 to 1.1)
PrimaryRocuronium Infusion Dose

The amount of rocuronium given by continuous infusion in mg/kg/hr to maintain one twitch of the train of four (TOF)

Time frame:
During surgery (2-8 hrs.)
Reported as:
Median · mg/kg/hr
Rocuronium Infusion Dose
mg/kg/hrRocuronium Infusion
Rocuronium Infusion Dose0.48 (0.36 to 0.6)
PrimaryMaximum Dose of Rocuronium

The maximum dose of rocuronium administered by a continuous infusion per patient to maintain one twitch of the train of four (TOF)

Time frame:
During the surgery (2-8 hrs.)
Reported as:
Count of participants · Participants
Maximum Dose of Rocuronium
ParticipantsRocuronium Infusion
0.1 to <0.4 mg/kg/hr1
0.4 to 0.6 mg/kg/hr41
>0.6 to 0.72 mg/kg/hr6
SecondaryRocuronium Infusion Time

Amount of time in minutes that patients received rocuronium infusion.

Time frame:
During the surgery (2-8 hrs.)
Reported as:
Median · minutes
Rocuronium Infusion Time
minutesRocuronium Infusion
Rocuronium Infusion Time201.5 (138.5 to 310)
SecondaryRocuronium Rescue Boluses

The number of patient that received rescue boluses of rocuronium in addition to the infusion to maintain one twitch of the train of four (TOF)

Time frame:
During the surgery (2-8 hrs.)
Reported as:
Count of participants · Participants
Rocuronium Rescue Boluses
ParticipantsRocuronium Infusion
Rocuronium Rescue Boluses26
SecondaryAnesthesia Time

The total amount of time patients were under anesthesia care in minutes.

Time frame:
During the surgery (2-8 hrs.)
Reported as:
Median · minutes
Anesthesia Time
minutesRocuronium Infusion
Anesthesia Time339 (250 to 445.5)
SecondarySurgical Time

The total amount of time from first incision to closure in minutes.

Time frame:
During the surgery (2-8 hrs.)
Reported as:
Median · minutes
Surgical Time
minutesRocuronium Infusion
Surgical Time225 (178 to 313)

Adverse events

Collected over 1 Day (day of surgery). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rocuronium Infusion0/48 (0%)0/48 (0%)0/48 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Rocuronium Infusion
<=18 years48
Between 18 and 65 years0
>=65 years0
Age, Continuous
Age, Continuous(years)Rocuronium Infusion
Median13 (8 to 16)
Sex: Female, Male
Sex: Female, Male(Participants)Rocuronium Infusion
Female15
Male33
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Rocuronium Infusion
Hispanic or Latino1
Not Hispanic or Latino47
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Rocuronium Infusion
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American4
White38
More than one race5
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Rocuronium Infusion
United States48
Height
Height(centimeters)Rocuronium Infusion
Median156.6 (125.4 to 173)
Weight
Weight(kilograms)Rocuronium Infusion
Median55.9 (29.5 to 69.3)

2 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2024 to primary completion in Apr 2025, 7 months.

Results were first posted in May 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2024
First posted
Jun 25, 2024
StartActual
Sep 12, 2024
Primary completionActual
Apr 24, 2025
CompletionActual
Apr 24, 2025
Results first posted
May 13, 2026
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06472284
Lead sponsor
Joseph D. Tobias
Responsible party
Joseph D. Tobias (Chief, Dept. of Anesthesiology & Pain Medicine, Nationwide Children's Hospital) — Sponsor-investigator
First posted
Jun 25, 2024
Start date
Sep 12, 2024
Primary completion
Apr 24, 2025
Completion
Apr 24, 2025
Results posted
May 13, 2026
Last update
May 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion